Press releases

Press Releases

Powered by Arx
Date Headline Read
Sep 30, 2025
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations
 View
Sep 25, 2025
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital Market Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Ca…
 View
Sep 11, 2025
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offeri…
 View
Sep 11, 2025
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses
 View
Sep 04, 2025
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204
 View
Sep 02, 2025
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will b…
 View
Aug 12, 2025
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Continued advancement of SIL204 preclinical program with strong efficacy data across multiple KRAS-driven cancer types; company strengthened financial position and maintains progress toward clinical trials Continued advancement of SIL204 preclinical program with strong efficac…
 View
Aug 01, 2025
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into defini…
 View
Jul 31, 2025
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Potential; Company on track for the initiation of a Phase 2/3 clinical trial in…
 View
Jul 16, 2025
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its strategic growth initiatives Trading on split-adjusted basis will begin at mar…
 View
Jul 09, 2025
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS Mutation with Results expected in the Near Future Company…
 View
May 29, 2025
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers
Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; Company to conduct additional preclinical study focused on lung cancer cell lin…
 View
May 21, 2025
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollar…
 View
May 13, 2025
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025 Significant advancem…
 View
Apr 23, 2025
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical Trials Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clini…
 View
Mar 28, 2025
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising clinical data from its first-generation product; Company sh…
 View
Mar 21, 2025
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly A…
 View
Mar 18, 2025
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding strengthens the company’s ability to deliver long term va…
 View
Mar 05, 2025
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic Cancer Cells Grow in Their Native Environment Silexion Therapeutics' Latest Data D…
 View
Feb 25, 2025
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Rel…
 View
Sep 03, 2024
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 2…
 View
Aug 15, 2024
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, res…
 View

Ilan Hadar- Chairman

55, has served as Managing Director of Silexion since April 2022 and as Chairman of the Board since May 2024. Ilan has been appointed as Chief Executive Officer of New Pubco. He has over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies, as described below, over which time period he has acquired the experience and skills to serve as a valuable member of the board of directors of a company such as Biomotion Sciences. before his current role at Silexion, Mr. Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) since November 2020. Before joining Painreform, Mr. Hadar served as Country Manager in Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions. Prior to his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Before his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world-leading company in digital printing and, prior to that, served as Finance Director at BAE Systems, the third-largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was the Chief Financial Officer at Mango DSP, a global leader in Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical company from 2019 to 2022. He received his MBA in Finance and Business Entrepreneurship and BA from The Hebrew University in Jerusalem, Israel.

Mirit Horenshtein Hadar- Chief Finanacial Officer

Has served as the Executive Vice President of Finance Affairs at Silexion since January 2024, and will be appointed as Chief Financial Officer of New Pubco effective upon the consummation of the Business Combination. From August 2023 to January 2024, Ms. Horenshtein Hadar served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity. Ms. Horenshtein Hadar has over 15 years ofcorporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech industries, where she has been instrumental in building financial infrastructures for growth, U.S. GAAP financial reporting and FP&A functions, and has led the accounting and reporting of complex M&A transactions, integration processes and public offerings. Prior to joining Silexion, from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies. Since December 2022, Ms. Horenshtein Hadar continues to serve as an external advisor to the finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar served as Senior Director of Finance and Head of FP&A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from July 2016 until December 2020. Prior to Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel, as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became a Qualified CPA in 2011 and received a BA in Accounting, Economics and Business Management from Tel Aviv University.

Orit Pollack–Shragai, M.Sc, MBA- VP Clinical Operations

Mrs. Pollack Shragai brings  over  two  decades  of relevant academic education, research and work experience in the biomed industry working for CRO, big pharma and start-up companies, managing local and international clinical trials (including mega trials) in drugs and medical devices. Prior to joining Silenseed, Mrs. Pollack Shragai served as Director of Clinical Operations and Active Advisor to several pharmaceutical companies 

Mrs. Pollack Shragai holds a  B.Sc  in  Food  Engineering  and  Biotechnology  from  the  Technion  in  Israel,  M.Sc  in Biotechnology  from  the  Hebrew  University  and  MBA  from  the  College  of  Management Academic Studies.

Michal Yaron- VP Regulatory Affairs

Mrs. Yaron holds 17 years of professional regulatory and product development experience across the pharmaceutical industry, with products from early stage through POC and regulatory approvals by multiple health authorities. Previously Mrs. Yaron held Regulatory Affairs managerial positions at Sol-Gel Technologies, Polypid, and Teva Pharmaceuticals Ltd. Mrs. Yaron Holds a M.Sc. degree in Chemistry.

Dr. Revital Maor Aloni

Dr. Revital Maor Aloni Joined Silenseed in December 2019 and led the quality of the KRAS-LODER from phase II. She also led the process for gaining a GMP approval from the Israeli Ministry of health for the LODER. Prior to joining Silenseed Dr. Maor Aloni has served as Director of Quality in SciVak Ltd. a biotechnology company from 2017, and prior to that as Director of Quality systems in Lumenis, a medical device company. Dr. Maor Aloni also served as senior manager in Aminolab Ltd. For 6 years as head of the Microbiology department and the chemistry department. Dr. Maor Aloni holds a Ph. D in microbiology from Ben-Gurion University in Beer-Sheva and Post-Doctorate from the Weizmann Institute of Science in Rehovot, Israel.

Dr. Racheli Malka Gabai

VP Pharmaceutical Development, Ph. D- Dr Gabai Malka Joined Silenseed in February 2009 and leads the development of the formulation and the production of the KRAS-LODER from the concept stage and up to Phase II. Dr Gabai Malka holds a B.Sc. in Chemistry and a M.Sc. in Chemistry both from the Hebrew University in Jerusalem and holds a Ph.D. and a Post-Doctorate in Chemistry from the Weizmann institute of science in Rehovot, Israel.

Dr Gabai Malka is a co-author of 12 scientific papers and co-inventor of 8 of the Silenseed’s granted patents.

Dr. Mitchell Shirvan - Chief Scientific and Development Officer

Has served as the Chief Scientific and Development Officer of Silexion since April 2022. Prior to joining Silexion, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previously holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held various positions of increasing responsibility at Teva Pharmaceutical Industries, including Senior Director, Strategic Business Planning and Senior Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.

Ilan Hadar – Chief Executive Officer

Mr. Hadar brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Ilan has been instrumental in building companies from start-ups to hundreds of millions of dollars in operations. He successfully took part in the development, approval, and launch of new pharmaceutical products in the U.S. and Israel. Before joining Seilexion, Ilan is served as the Chief Executive Officer of Painreform Ltd. (“PRFX”) from Nov. 2020 to June 2024. Painreform proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration. Prior to joining Painreform, Ilan served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since 2014, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., as well as a focus on capital markets and M&A. Prior to Foamix, Ilan was Finance Director at Pfizer Pharmaceutical Ltd., where he oversaw all commercial, financial and operational activities of the local entity. Ilan served on the Board of Directors at Kadimastem, a public Israeli biopharmaceutical company (TASE: KDST). Ilan received his MBA in Finance and Business Entrepreneurship and B.A. degree at The Hebrew University in Jerusalem, Israel.